CU20140005A7 - Una nueva composición terapéutica que contiene apomorfina como principio activo - Google Patents

Una nueva composición terapéutica que contiene apomorfina como principio activo

Info

Publication number
CU20140005A7
CU20140005A7 CUP2014000005A CU20140005A CU20140005A7 CU 20140005 A7 CU20140005 A7 CU 20140005A7 CU P2014000005 A CUP2014000005 A CU P2014000005A CU 20140005 A CU20140005 A CU 20140005A CU 20140005 A7 CU20140005 A7 CU 20140005A7
Authority
CU
Cuba
Prior art keywords
therapeutic composition
active principle
new therapeutic
apomorphine
contains apomorphine
Prior art date
Application number
CUP2014000005A
Other languages
English (en)
Other versions
CU24159B1 (es
Inventor
Michael Dey
Joel Richard
Marie-Madeleine Baronnet
Nathalie Mondoly
Laurent Bertocchi
Jeremiah Harnett
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of CU20140005A7 publication Critical patent/CU20140005A7/es
Publication of CU24159B1 publication Critical patent/CU24159B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que contiene apomorfina como principio farmacéutico activo, codisolvente, antioxidante, agua con un pH mayor que 4. La formulación farmacéutica es adecuada para la administración parenteral para el tratamiento de la enfermedad de Parkinson.
CU20140005A 2011-07-11 2012-07-11 Una nueva composición terapéutica que contiene apomorfina como principio activo CU24159B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290320A EP2545905A1 (en) 2011-07-11 2011-07-11 A new therapeutical composition containing apomorphine as active ingredient
PCT/EP2012/002916 WO2013007381A1 (en) 2011-07-11 2012-07-11 A new therapeutical composition containing apomorphine as active ingredient

Publications (2)

Publication Number Publication Date
CU20140005A7 true CU20140005A7 (es) 2014-04-24
CU24159B1 CU24159B1 (es) 2016-03-31

Family

ID=46514305

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20140005A CU24159B1 (es) 2011-07-11 2012-07-11 Una nueva composición terapéutica que contiene apomorfina como principio activo

Country Status (30)

Country Link
US (4) US11026938B2 (es)
EP (2) EP2545905A1 (es)
JP (2) JP6356064B2 (es)
KR (1) KR101990897B1 (es)
CN (2) CN108434094A (es)
AU (1) AU2012283381B2 (es)
BR (1) BR112014000306B1 (es)
CA (1) CA2841807C (es)
CL (1) CL2014000050A1 (es)
CO (1) CO6870038A2 (es)
CR (1) CR20140005A (es)
CU (1) CU24159B1 (es)
DO (1) DOP2014000003A (es)
EA (1) EA025870B1 (es)
EC (1) ECSP14013200A (es)
GE (2) GEP20196969B (es)
GT (1) GT201400003A (es)
IL (1) IL230308A (es)
IN (1) IN2014DN00090A (es)
MA (1) MA35411B1 (es)
MX (2) MX389600B (es)
MY (1) MY168212A (es)
NI (1) NI201400003A (es)
PE (1) PE20141539A1 (es)
PH (1) PH12014500065A1 (es)
SG (1) SG10201605491PA (es)
TN (1) TN2014000001A1 (es)
UA (1) UA113962C2 (es)
WO (1) WO2013007381A1 (es)
ZA (1) ZA201309711B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
AU2013273138B2 (en) * 2012-06-05 2017-06-15 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
EP3237386A2 (en) * 2014-12-23 2017-11-01 Neuroderm Ltd Crystal forms of apomorphine and uses thereof
MA43042A (fr) * 2015-09-28 2018-08-08 Ever Neuro Pharma Gmbh Composition aqueuse d'apomorphine pour une administration sous-cutanée
WO2020243538A1 (en) * 2019-05-31 2020-12-03 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient
WO2021026421A1 (en) * 2019-08-07 2021-02-11 Aclipse One Inc. Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
CN115666571B (zh) 2020-05-20 2024-11-05 美德阿利克斯株式会社 含有阿扑吗啡的经皮吸收型制剂
WO2022271537A1 (en) * 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US20240335379A1 (en) * 2021-08-05 2024-10-10 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine
US20250361252A1 (en) 2022-06-15 2025-11-27 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1662566A1 (ru) * 1988-03-05 1991-07-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Способ стабилизации инъекционного раствора апоморфина
JP2822049B2 (ja) * 1989-02-02 1998-11-05 ゼリア新薬工業株式会社 水性製剤組成物
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en) 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ITMI20011321A1 (it) * 2001-06-22 2002-12-22 Chiesi Farma Spa Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US6939094B2 (en) 2003-01-28 2005-09-06 Macro Technologies Inc. Autonomous power interface for modifying limited rotation speed of a machine
CA2520121A1 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
MX2008014910A (es) 2006-05-24 2009-01-23 Bayer Schering Pharma Ag Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.
US20080171072A1 (en) * 2006-08-11 2008-07-17 Frank Burczynski Ocular inserts containing apomorphine
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient

Also Published As

Publication number Publication date
US20160310480A1 (en) 2016-10-27
CN108434094A (zh) 2018-08-24
KR101990897B1 (ko) 2019-06-19
JP2014518285A (ja) 2014-07-28
CR20140005A (es) 2014-07-21
SG10201605491PA (en) 2016-08-30
MX389600B (es) 2025-03-19
US11766431B2 (en) 2023-09-26
EP2731589A1 (en) 2014-05-21
EP2545905A1 (en) 2013-01-16
CU24159B1 (es) 2016-03-31
BR112014000306B1 (pt) 2022-03-29
MY168212A (en) 2018-10-15
CN103826612A (zh) 2014-05-28
EA025870B1 (ru) 2017-02-28
NI201400003A (es) 2015-10-12
KR20140072861A (ko) 2014-06-13
US20180098981A1 (en) 2018-04-12
JP2017081947A (ja) 2017-05-18
MX2021010046A (es) 2021-09-21
IN2014DN00090A (es) 2015-05-15
EA201400067A1 (ru) 2015-02-27
US20210244724A1 (en) 2021-08-12
GEAP201813377A (en) 2018-12-25
CA2841807A1 (en) 2013-01-17
AU2012283381A1 (en) 2014-02-06
CO6870038A2 (es) 2014-02-20
MX2014000454A (es) 2014-09-01
BR112014000306A2 (pt) 2017-02-07
DOP2014000003A (es) 2014-06-01
US20140128422A1 (en) 2014-05-08
IL230308A (en) 2017-04-30
GT201400003A (es) 2017-09-28
MA35411B1 (fr) 2014-09-01
GEP20196969B (en) 2019-04-25
ZA201309711B (en) 2014-08-27
JP6356064B2 (ja) 2018-07-11
US11026938B2 (en) 2021-06-08
CL2014000050A1 (es) 2014-08-18
PH12014500065A1 (en) 2014-02-17
TN2014000001A1 (en) 2015-07-01
CA2841807C (en) 2018-02-20
PE20141539A1 (es) 2014-10-25
WO2013007381A1 (en) 2013-01-17
ECSP14013200A (es) 2014-04-30
CN103826612B (zh) 2020-07-28
AU2012283381B2 (en) 2017-07-27
UA113962C2 (xx) 2017-04-10

Similar Documents

Publication Publication Date Title
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CL2020000747A1 (es) Formulaciones de niraparib.
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
BR112012023021A2 (pt) compostos de indazol e seus usos
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2015008396A (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
ECSP14013155A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112014017902A2 (pt) Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
BR112015019307A2 (pt) derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada
NI201200196A (es) Agentes terapéuticos 976
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Legal Events

Date Code Title Description
FG Grant of patent